Zobrazeno 1 - 10
of 481
pro vyhledávání: '"Tsen-Fang TSAI"'
Autor:
Gil Yosipovitch, MD, Brian S. Kim, MD, Shawn G. Kwatra, MD, Nicholas K. Mollanazar, MD, Sonja Ständer, MD, Takahiro Satoh, MD, PhD, Pedro Mendes-Bastos, MD, Tsen-Fang Tsai, MD, Elizabeth Laws, PhD, Michael C. Nivens, PhD, Jennifer Maloney, MD, Genming Shi, PhD, Ashish Bansal, MD, MBA, Ariane Dubost-Brama, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 163-174 (2024)
Background: Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis. Objective: To obtain a more precise estimate of onset and magnitude of treatme
Externí odkaz:
https://doaj.org/article/711afba8cadd4d1c95210d2031b7c4d3
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2607-2620 (2024)
Abstract Introduction Knowing the remission duration after biologics discontinuation in patients with psoriasis is important, especially when disease relapse is defined as the restart of systemic agents, because it also reflects the real-world clinic
Externí odkaz:
https://doaj.org/article/897de82a93e14f7386036385d0f67e4f
Publikováno v:
Indian Journal of Dermatology, Vol 69, Iss 3, Pp 264-267 (2024)
Biologics have expanded the armamentarium for psoriasis, but there has been a growing concern about the risk of lymphoma in patients under tumour necrosis factor (TNF)-α inhibitor and methotrexate. Besides, the mRNA-based coronavirus disease 2019 (C
Externí odkaz:
https://doaj.org/article/d283698e06214b5897ade87b71fd9de5
Autor:
Chao-Kai Hsu, Yu-Huei Huang, Chung-Hsing Chang, Yi-Ju Chen, Tsu-Man Chiu, Wen-Hung Chung, Chiau-Sheng Jang, Shang-Hung Lin, Chun-Wei Lu, Nan-Lin Wu, Sebastian Yu, Tsen-Fang Tsai
Publikováno v:
Dermatologica Sinica, Vol 42, Iss 2, Pp 98-109 (2024)
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening skin disease characterized by relapsing and remitting flares of sterile neutrophilic pustules and systemic inflammation. The definition of GPP is inconsistent globally, with
Externí odkaz:
https://doaj.org/article/edb20caf0f234c9894d426e9112013df
Publikováno v:
Taiwanese Journal of Obstetrics & Gynecology, Vol 63, Iss 3, Pp 405-408 (2024)
Objective: Impetigo herpetiformis (IH) is a rare form of pustular psoriasis which may result in maternal and fetal morbidity and even mortality. Deficiency of interleukin-36 receptor antagonist (DITRA) is the most frequently identified genetic defect
Externí odkaz:
https://doaj.org/article/61d6879d7c29422494843b20bb3ab0a7
Autor:
Yao-Tsung Yeh, Tsen-Fang Tsai
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 59-81 (2024)
Abstract Introduction Drugs and vaccines have been less studied as inducing or aggravating factors for psoriatic arthritis (PsA) compared with psoriasis. Thus, the present study collected and summarized the publications to date about this issue. Meth
Externí odkaz:
https://doaj.org/article/15e9b68bf2b4400888cf37735d3ccf47
Autor:
Tsen-Fang Tsai, Min Zheng, Yangfeng Ding, Zhiqi Song, Quanzhong Liu, Ying Chen, Hanzhao Hu, Jinhua Xu
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3097-3110 (2023)
Abstract Introduction Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening skin disease. The global Effisayil 1 study investigated the efficacy and safety of spesolimab, a humanized monoclonal antibody targeting the IL-36 r
Externí odkaz:
https://doaj.org/article/c1c887e2b8cd4b5c9b636241d0b82f68
Autor:
Chang-Yu Hsieh, Tsen-Fang Tsai
Publikováno v:
Dermatologica Sinica, Vol 42, Iss 2, Pp 152-153 (2024)
Externí odkaz:
https://doaj.org/article/a6a5a2ca3f5f4e22aae10ace990e2af9
Autor:
Chia-Jung Hsu, Tsen-Fang Tsai
Publikováno v:
Dermatologica Sinica, Vol 42, Iss 2, Pp 164-165 (2024)
Externí odkaz:
https://doaj.org/article/d60c8176b54d4842994e0862545fbcc4
Autor:
Susan Taylor, Neil J. Korman, Tsen-Fang Tsai, Yutaka Shimomura, Meghan Feely, Yves Dutronc, Wen-Shuo Wu, Najwa Somani, Antonella Tosti
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3181-3191 (2023)
Abstract Background Baricitinib, an oral selective JAK1/JAK2 inhibitor, is approved for the treatment of adults with severe alopecia areata (AA). Objective To evaluate differences in response up to week 52 among subgroups based on the baseline severi
Externí odkaz:
https://doaj.org/article/ec3994a4004f469cadd3311b93a0b34b